Wright Don - 11 Jun 2026 Form 4 Insider Report for International Stem Cell CORP (ISCO)

Reporting relationship: Director
Issuer ticker: ISCO
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 20:31:59 UTC
Prior SEC filing: 20 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Russell Kern, as Attorney-in-Fact

Key filing fact

Wright Don filed Form 4 for International Stem Cell CORP (ISCO) on 23 Jun 2026.

Key facts

This page summarizes Wright Don's Form 4 filing for International Stem Cell CORP (ISCO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 23 Jun 2026, 20:31.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405212 Primary reporting owner

Don Wright

Relationship: Director
Address: C/O INTERNATIONAL STEM CELL CORP., 9745 BUSINESSPARK AVENUE, SAN DIEGO
Signature: /s/ Russell Kern, as Attorney-in-Fact
Signature date: 24 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ISCO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $0.1700
Footnotes: F1

ISCO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +182,584
Change %
Price: $0.000000^*
Shares after: 182,584
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 182,584
Exercise price: $0.1780
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying such option shall vest on the earlier of (a) June 11, 2027, or (b) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant.

Footnote F2

The shares underlying such option shall vest in equal quarterly increments through June 11, 2027, with the first increment vesting on September 11, 2026.